Trials / Completed
CompletedNCT00167960
Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit
Effects on the Emergence and Transmission of Vancomycin-Resistant Enterococci After Changes in Antibiotic Use in a Hematology Unit.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,500 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Piperacillin/tazobactam and other β-lactam/β-lactamase |
Timeline
- Start date
- 2005-01-01
- First posted
- 2005-09-14
- Last updated
- 2007-03-15
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00167960. Inclusion in this directory is not an endorsement.